| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
8,409 |
7,596 |
$1.47M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
6,994 |
6,027 |
$1.20M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,630 |
16,148 |
$797K |
| 87634 |
|
8,447 |
7,648 |
$313K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
8,043 |
7,222 |
$312K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,470 |
4,063 |
$211K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
9,595 |
8,606 |
$206K |
| 87581 |
|
9,467 |
8,291 |
$200K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,115 |
2,481 |
$196K |
| 87486 |
|
8,869 |
7,724 |
$185K |
| 87640 |
|
9,729 |
8,807 |
$175K |
| 87541 |
|
7,450 |
6,540 |
$158K |
| 87498 |
|
8,750 |
7,697 |
$150K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,525 |
2,714 |
$129K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,224 |
2,841 |
$110K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,696 |
1,366 |
$81K |
| 87641 |
|
3,710 |
3,255 |
$57K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,970 |
2,376 |
$54K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,228 |
2,534 |
$44K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,023 |
2,833 |
$44K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,172 |
5,381 |
$41K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,292 |
5,326 |
$40K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,334 |
1,946 |
$23K |
| 71046 |
Radiologic examination, chest; 2 views |
1,353 |
1,116 |
$17K |
| 80053 |
Comprehensive metabolic panel |
1,169 |
1,044 |
$7K |
| 80061 |
Lipid panel |
542 |
467 |
$3K |
| 90674 |
|
329 |
254 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
116 |
85 |
$2K |
| 80051 |
|
603 |
507 |
$1K |
| 81003 |
|
716 |
615 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
116 |
104 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,366 |
2,745 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
325 |
202 |
$1K |
| 84460 |
|
211 |
187 |
$707.00 |
| 82977 |
|
190 |
172 |
$665.00 |
| 84075 |
|
212 |
188 |
$606.00 |
| 84450 |
|
211 |
187 |
$606.00 |
| 82565 |
|
212 |
188 |
$606.00 |
| 82247 |
|
236 |
205 |
$545.00 |
| 82040 |
|
225 |
201 |
$540.00 |
| 84520 |
|
212 |
188 |
$505.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
56 |
44 |
$464.00 |
| 82947 |
|
223 |
200 |
$424.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
525 |
439 |
$391.67 |
| 84155 |
|
212 |
188 |
$364.61 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
176 |
111 |
$325.00 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
206 |
177 |
$307.84 |
| 84439 |
|
65 |
62 |
$297.00 |
| 87807 |
|
40 |
38 |
$275.00 |
| 87999 |
|
1,853 |
1,735 |
$270.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,156 |
2,557 |
$252.37 |
| 90714 |
|
36 |
25 |
$211.60 |
| 94060 |
|
14 |
13 |
$160.47 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
37 |
29 |
$156.00 |
| 99051 |
|
748 |
602 |
$136.42 |
| 80305 |
|
33 |
32 |
$136.11 |
| 93000 |
|
17 |
16 |
$135.80 |
| 86318 |
|
39 |
27 |
$117.00 |
| 84153 |
|
17 |
13 |
$100.00 |
| 72100 |
|
14 |
13 |
$95.40 |
| 84703 |
|
16 |
15 |
$72.00 |
| 86308 |
|
15 |
12 |
$60.53 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
18 |
14 |
$5.82 |
| 36415 |
Collection of venous blood by venipuncture |
6,380 |
5,606 |
$2.00 |
| 3074F |
|
10,131 |
9,442 |
$0.00 |
| 3079F |
|
2,064 |
1,949 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
6,472 |
6,074 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
898 |
853 |
$0.00 |
| 3075F |
|
1,110 |
1,056 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
208 |
147 |
$0.00 |
| 3080F |
|
76 |
66 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
52 |
44 |
$0.00 |
| 3048F |
|
29 |
28 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
20,430 |
18,513 |
$0.00 |
| 3078F |
|
9,185 |
8,621 |
$0.00 |
| 99072 |
|
4,940 |
4,526 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
10,761 |
9,780 |
$0.00 |
| 3077F |
|
116 |
98 |
$0.00 |
| 3051F |
|
14 |
13 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
34 |
31 |
$0.00 |